Eli Lilly and Company (NYSE:LLY) is one of the top S&P 500 stocks by index weight. On April 15, BMO Capital reiterated an ...

Regulators approved the company's GLP-1 weight loss pill, Foundayo, at the beginning of April.

With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift ...

The pharmaceutical’s Foundayo drug takes on oral Wegovy, the popular treatment from Novo Nordisk.

The results seen with Foundayo, also known as orforglipron, enabled Lilly’s late-stage Achieve-4 study to hit its primary ...

The FDA has approved the second GLP-1 pill for overweight and obesity. How does it compare to the Wegovy oral pill?

Eli Lilly (NYSE:LLY) reported positive phase 3 ACHIEVE-4 results for its once-daily oral GLP-1 therapy Foundayo (orforglipron ...

"Lilly debuts more Foundayo data as FDA requests post-marketing trials" was originally created and published by ...

Lilly plans to file Foundayo with the FDA for type 2 diabetes by end of Q2 after the ACHIEVE-4 trial met its primary ...

Novo Nordisk received 3,071 prescriptions in the first four days after its January 5 U.S. debut. ・Eli Lilly said that ...

At the heart of the request is whether taking Foundayo - made with a new active ingredient called orforglipron - could be ...

By Sriparna Roy and Sahil Pandey April 16 (Reuters) - Eli Lilly said on Thursday its newly approved obesity pill was not ...